Abstract：Objective To investigate the serum level of severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2)-specific RBD IgG antibody (SARS-CoV-2 IgG antibody for short) in children with SARS-CoV-2 Omicron variant infection during the recovery stage, as well as the protective effect of SARS-CoV-2 vaccination against Omicron infection. Methods A retrospective analysis was performed on 110 children who were diagnosed with coronavirus disease 2019 (COVID-19) caused by SARS-CoV-2 Omicron variant infection in Tianjin of China from January 8 to February 7, 2022. According to the status of vaccination before diagnosis, they were divided into a booster vaccination (3 doses) group with 2 children, a complete vaccination (2 doses) group with 90 children, an incomplete vaccination (1 dose) group with 5 children, and a non-vaccination group with 13 children. The clinical data and IgG level were compared among the 4 groups. Results The complete vaccination group had a significantly higher age than the non-vaccination group at diagnosis (P<0.05), and there was a significant difference in the route of transmission between the two groups (P<0.05). There were no significant differences among the four groups in sex, clinical classification, and re-positive rate of SARS-CoV-2 nucleic acid detection (P>0.05). All 97 children were vaccinated with inactivated vaccine, among whom 85 children (88%) were vaccinated with BBIBP-CorV Sinopharm vaccine (Beijing Institute of Biological Products, Beijing, China). At 1 month after diagnosis, the booster vaccination group and the complete vaccination group had a significantly higher level of SARS-CoV-2 IgG antibody than the non-vaccination group (P<0.05), and at 2 months after diagnosis, the complete vaccination group had a significantly higher level of SARS-CoV-2 IgG antibody than the non-vaccination group (P<0.05). For the complete vaccination group, the level of SARS-CoV-2 IgG antibody at 2 months after diagnosis was significantly lower than that at 1 month after diagnosis (P<0.05). Conclusions Vaccination with inactivated SARS-CoV-2 vaccine has a protective effect against Omicron infection in children. For children vaccinated with 2 doses of the vaccine who experience Omicron infection, there may be a slight reduction in the level of SARS-CoV-2 IgG antibody at 2 months after diagnosis. Citation:Chinese Journal of Contemporary Pediatrics, 2022, 24(7): 736-741
ZHANG Ping-Ping,GUO Yan-Ting,CHU Yu-Qin et al. Change in serum IgG antibody during the recovery stage of Omicron variant infection in children: an analysis of 110 cases[J]. CJCP, 2022, 24(7): 736-741.
Iyer AS, Jones FK, Nodoushani A, et al. Persistence and decay of human antibody responses to the receptor binding domain of SARS-CoV-2 spike protein in COVID-19 patients[J]. Sci Immunol, 2020, 5(52): eabe0367. PMID: 33033172. PMCID: PMC7857394. DOI: 10.1126/sciimmunol.abe0367.
Nyberg T, Ferguson NM, Nash SG, et al. Comparative analysis of the risks of hospitalisation and death associated with SARS-CoV-2 omicron (B.1.1.529) and delta (B.1.617.2) variants in England: a cohort study[J]. Lancet, 2022, 399(10332): 1303-1312. PMID: 35305296. PMCID: PMC8926413. DOI: 10.1016/S0140-6736(22)00462-7.
13 Dorabawila V, Hoefer D, Bauer UE, et al. Effectiveness of the BNT162b2 vaccine among children 5-11 and 12-17 years in New York after the emergence of the Omicron variant[J]. medRxiv[Preprint]. (2022-02-28) [2022-03-25]. DOI: 10.1101/2022.02.25.22271454.
16 Seaman MS, Siedner MJ, Boucau J, et al. Vaccine breakthrough infection with the SARS-CoV-2 Delta or Omicron (BA.1) variant leads to distinct profiles of neutralizing antibody responses[J]. medRxiv[Preprint]. (2022-03-03) [2022-04-16]. PMID: 35262094. PMCID: PMC8902886. DOI: 10.1101/2022.03.02.22271731.
17 Wang K, Cao Y, Zhou Y, et al. A third dose of inactivated vaccine augments the potency, breadth, and duration of anamnestic responses against SARS-CoV-2[J]. medRxiv[Preprint]. (2021-09-05) [2022-03-05]. DOI: 10.1101/2021.09.02.21261735.
Sughayer MA, Souan L, Abu Alhowr MM, et al. Comparison of the effectiveness and duration of anti-RBD SARS-CoV-2 IgG antibody response between different types of vaccines: implications for vaccine strategies[J]. Vaccine, 2022, 40(20): 2841-2847. PMID: 35397946. PMCID: PMC8971065. DOI: 10.1016/j.vaccine.2022.03.069.
